A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
Jodi L. Karnell(Integrated BioTherapeutics (United States)), Jörn Drappa(Integrated BioTherapeutics (United States)), Manuel Baca(Tri-Institutional Therapeutics Discovery Institute), Rachel Moate, Ximing Xiong, Isharat Yusuf(University of California, Irvine), Stacey Drabic, M. Albulescu(AstraZeneca (United Kingdom)), Vaheh Oganesyan, Steven Eck, Thomas Thisted, Rachel Ettinger(Autoimmune Technologies (United States)), Katie Streicher(AstraZeneca (United States)), Michele Gunsior(Integrated BioTherapeutics (United States)), Jing Li(Guangzhou Medical University), Yan Li(Icahn School of Medicine at Mount Sinai), Ronald Herbst, Melissa de los Reyes, David Howe, Ulf Müller‐Ladner(Kerckhoff Klinik), Liangwei Wang(Integrated BioTherapeutics (United States))
Cited by 98
Related Papers
Genome sequencing in microfabricated high-density picolitre reactors
|Nature|2005|7.7k
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
|Proceedings of the National Academy of Sciences|1999|632
IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE
|Nature Communications|2018|563
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130
|Proceedings of the National Academy of Sciences|2000|465
Germinal Center T Follicular Helper Cell IL-4 Production Is Dependent on Signaling Lymphocytic Activation Molecule Receptor (CD150)
|The Journal of Immunology|2010|406